Clinicopathologic and survival patterns among prostate carcinosarcoma patients in the U.S. An analysis of SEER database
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Prostatic carcinosarcoma is a rare and aggressive cancer. This study analyzed SEER data, finding a 5-year survival rate of 11.9%, highlighting the need for better understanding and treatment.
Area Of Science
- Oncology
- Urologic Pathology
Background
- Prostatic carcinosarcoma is an extremely rare malignancy, accounting for less than 1% of all prostate neoplasms.
- Existing literature is sparse, primarily consisting of limited case studies.
Purpose Of The Study
- To investigate the demographic, clinical, and histologic factors associated with prostatic carcinosarcoma.
- To analyze the prognosis and survival rates for patients diagnosed with this rare cancer.
Main Methods
- Utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify cases from 2000-2018.
- Collected demographic (age, race, sex) and clinical data (tumor grade, stage, size, lymph node status, metastasis, treatment).
Main Results
- Median age at diagnosis was 72 years; 93% of cases were in White individuals.
- Tumor size frequently exceeded 5 cm (84.2%), with distant metastasis to the liver and lung observed.
- The five-year overall survival rate was critically low at 11.9%.
Conclusions
- Prostatic carcinosarcoma predominantly affects men in their seventh decade.
- Advanced tumor stage is a significant indicator of poor survival.
- The aggressive nature necessitates further research for improved personalized therapeutic strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...